^
    3d
    A Clinical Trial of OM336 to Help Immunized Patients Become Eligible for Kidney Transplantation (2025-523222-40-00)
    P1/2, N=6, Medical University Of Vienna
    New P1/2 trial
    |
    dexamethasone • valacyclovir
    4d
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=260, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • TQB2934
    4d
    Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Candid Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    6d
    RISE: Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto
    New trial
    |
    Elrexfio (elranatamab-bcmm)
    8d
    BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Medical College of Wisconsin | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    Lynozyfic (linvoseltamab-gcpt)
    8d
    QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P2 trial
    |
    lenalidomide • dexamethasone • pomalidomide • dexamethasone injection
    10d
    Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Completed --> Active, not recruiting
    Enrollment closed
    |
    podentamig (MK-4002)
    10d
    Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) (clinicaltrials.gov)
    P1, N=200, Recruiting, Ichnos Sciences SA | N=85 --> 200
    Enrollment change • First-in-human
    |
    ABBV-2001
    10d
    DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (clinicaltrials.gov)
    P1/2, N=153, Recruiting, GlaxoSmithKline | N=32 --> 153
    Enrollment change
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    10d
    MAGNETISMM-5: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (clinicaltrials.gov)
    P3, N=944, Recruiting, Pfizer | N=361 --> 944
    Enrollment change
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    10d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | N=468 --> 795
    Enrollment change
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    10d
    BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Institute of Hematology & Blood Diseases Hospital, China | N=20 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal